Immunotherapy uses a person’s own immune system to fight cancer.

Immune checkpoint inhibitors are one class of immunotherapy that block specific proteins from slowing the immune response.

As a result, immune cells become more active and can more effectively kill cancer cells.

However, most patients either respond poorly to checkpoint inhibitors or eventually become resistant to the treatment.

In a study published in Nature, University of Michigan researchers have identified that the balance between two proteins—STAT3 and STAT5—is important for making tumours vulnerable to immune checkpoint therapy, and targeting STAT3 degradation is a potential novel cancer immunotherapy strategy.

“Resistance to cancer immunotherapy is a huge issue for cancer patients,” said Weiping Zou, M.D., Ph.D., professor of surgery and pathology and a member of Rogel Cancer Centre.

“That’s why it’s important to understand the underlying mechanisms and figure out how to deal with this problem.”

As Zou describes, the immune system is like a military unit.

T cells function as soldiers and are responsible for killing tumour cells.

There are also generals, such as dendritic cells, that give out instructions on where and how the T cells are needed.

Dendritic cells patrol tissues, capture proteins that look abnormal and present these to T cells, thereby activating them.

Using RNA sequencing databases of cancer patients, the researchers found that STAT3 and STAT5 work together to control the quantity of dendritic cells.

Although researchers have known that STAT3 is a cancer target for many years, these results uncovered a previously unknown mechanism of immune checkpoint resistance." - Shaomeng Wang, Ph.D.

Through transcriptional signalling, each protein activates different types of genes that affect how dendritic cells function.

Patients who were responsive to checkpoint inhibitors had higher STAT5 signalling and lower STAT3 signalling.

Using mouse models, the researchers showed that STAT3 counteracts the effects of STAT5, preventing dendritic cells from maturing and activating T cells.

The results were consistent across different tumours, including those in the skin, ovary, breast, lung and colon.

“Although researchers have known that STAT3 is a cancer target for many years, these results uncovered a previously unknown mechanism of immune checkpoint resistance,” said Shaomeng Wang, Ph.D., professor of internal medicine and pharmacology and a member of Rogel Cancer Centre.

“Unfortunately, STAT3 is also hard to target and has been considered undruggable.”

In this study, the team turned to a system that already exists in our body.

“Our bodies contain a protein degradation system, which clears out damaged proteins,” Wang said.

“Our approach was to recruit that machinery to degrade STAT3.”

The team developed and used two types of molecules, SD-36 and SD-2301, to target STAT3 for protein degradation.

In both cell lines and mouse models, STAT3 degradation in dendritic cells boosted immunity and increased STAT5 signalling.

Both molecules were also effective in treating large, advanced tumours and those that were resistant to immune checkpoint inhibitors.

“Our next step is to conduct clinical trials of our most promising STAT3 degraders,” Zou said.

“Since STAT3 is often activated in many cancer types, we are hopeful that these molecules will help a large population of patients.”

Source: Michigan Medicine - University of Michigan